Journal of Nippon Medical School: Vol.71 No.6 page.384

Journal of Nippon Medical School

Select Language
in Japanese < > in English

Full Text of this Article

in English PDF (151K)

ArticleTitle Prognostic Significance of Ki-67 Antigen Immunostaining (MIB-1 Monoclonal Antibody) in Ovarian Cancer

AuthorList Shunji Mita¹, Akihito Nakai¹, Shotaro Maeda² and Toshiyuki Takeshita¹

Affiliation ¹Department of Obstetrics and Gynecology, Nippon Medical School
²Department of Pathology II, Nippon Medical School

Language EN

Volume 71

Issue 6

Year 2004

Page 384-391

Received July 23, 2004

Accepted September 3, 2004

Keywords ovarian cancer, Ki-67 antigen, MIB-1 monoclonal antibody, prognosis

Abstract Objective: To assess the potential usefulness of Ki-67 antigen expression as a predictor of outcome in ovarian cancer through the analysis of MIB-1 monoclonal antibody reactivity.
Methods: Cell proliferation and clinicopathologic variables were assessed in 26 patients with primary epithelial ovarian cancer who had undergone exploratory laparotomy. The expression of primary tumor proliferation related to Ki-67 antigen was immunohistochemically evaluated by MIB-1 monoclonal antibody.
Results: The value of Ki-67 labeling index (LI) ranged between 0 and 92.6% with a mean of 48.9%. Ki-67 LI correlated well with the mitotic index, but not the histological subtype. Ki-67 LI of more than 40%was defined as a higher proliferating tumor by a receiver operating characteristic curve analysis. Higher proliferating tumors were identified in 14 patients (54% of all subjects). The patients with higher proliferating tumors had a statistically significantly worse prognosis compared with those with lower proliferating tumors (p<0.001).
Conclusions: The present study demonstrates that the proliferating index detected by Ki-67 antigen immunostaining is a useful factor for predicting the survival of patients with ovarian cancer.

Correspondence to Shunji Mita, MD, Department of Obstetrics and Gynecology, Tama Nagayama Hospital, Nippon Medical School, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan
mita@nms.ac.jp

ArticleTitle	Prognostic Significance of Ki-67 Antigen Immunostaining (MIB-1 Monoclonal Antibody) in Ovarian Cancer
AuthorList	Shunji Mita¹, Akihito Nakai¹, Shotaro Maeda² and Toshiyuki Takeshita¹
Affiliation	¹Department of Obstetrics and Gynecology, Nippon Medical School ²Department of Pathology II, Nippon Medical School
Language	EN
Volume	71
Issue	6
Year	2004
Page	384-391
Received	July 23, 2004
Accepted	September 3, 2004
Keywords	ovarian cancer, Ki-67 antigen, MIB-1 monoclonal antibody, prognosis
Abstract	Objective: To assess the potential usefulness of Ki-67 antigen expression as a predictor of outcome in ovarian cancer through the analysis of MIB-1 monoclonal antibody reactivity. Methods: Cell proliferation and clinicopathologic variables were assessed in 26 patients with primary epithelial ovarian cancer who had undergone exploratory laparotomy. The expression of primary tumor proliferation related to Ki-67 antigen was immunohistochemically evaluated by MIB-1 monoclonal antibody. Results: The value of Ki-67 labeling index (LI) ranged between 0 and 92.6% with a mean of 48.9%. Ki-67 LI correlated well with the mitotic index, but not the histological subtype. Ki-67 LI of more than 40%was defined as a higher proliferating tumor by a receiver operating characteristic curve analysis. Higher proliferating tumors were identified in 14 patients (54% of all subjects). The patients with higher proliferating tumors had a statistically significantly worse prognosis compared with those with lower proliferating tumors (p<0.001). Conclusions: The present study demonstrates that the proliferating index detected by Ki-67 antigen immunostaining is a useful factor for predicting the survival of patients with ovarian cancer.
Correspondence to	Shunji Mita, MD, Department of Obstetrics and Gynecology, Tama Nagayama Hospital, Nippon Medical School, 1-7-1 Nagayama, Tama, Tokyo 206-8512, Japan mita@nms.ac.jp